Current Management of Retinopathy of Prematurity

Purpose of Review: This review aims to provide an update on the recent major advances in the management of retinopathy of prematurity (ROP). Recent Findings: There have been a number of major advances in our understanding and management of ROP over the last decade: (1) The advent of improved imaging techniques and technological infrastructure has led to the increased use of telemedicine and potential use of artificial intelligence to enhance access to care for children at risk of developing ROP; (2) the International Classification of Retinopathy of Prematurity (ICROP) 3rd edition has provided updates in classification of ROP and response of ROP to treatment; and (3) the treatment paradigm has shifted from laser therapy exclusively to now having the option of anti-vascular endothelial growth factor (VEGF) therapy. This has led to greater interest in trying to better understand the possible adverse events related to systemic and local VEGF suppression. Summary: There is a greater understanding in the diagnosis and treatment of ROP and its response to treatment. The advent of anti-VEGF therapy has provided ROP providers with a treatment modality that may lead to improved visual outcomes without the need for peripheral retinal ablation. However, there remain questions regarding systemic and local adverse events. Laser photocoagulation continues to be an effective primary therapy and may also be needed after or in conjunction with anti-VEGF treatment.